Quick Summary — IMAX scores higher on quality with 7.8/10 vs LLYVA's 4.4/10. IMAX trades at $40.50 while LLYVA trades at $95.26. Both analyzed daily using SEC EDGAR data across 13 institutional models.
IMAX scores higher with a 7.8/10 quality rating vs LLYVA's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $40.50, IMAX trades +53.9% above its Bayesian DCF fair value of $18.66, while LLYVA at $95.26 trades +76.6% above its estimate of $22.28. LLYVA shows a wider gap between price and intrinsic value.
IMAX earns a Quality of Company score of 7.8/10 compared to LLYVA's 4.4/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both IMAX and LLYVA to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both IMAX and LLYVA operate in Entertainment, which has 50 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare IMAX vs LLYVA differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.